On November 24, the answer to the mystery was revealed: a high-level shot.
Purchase of Xianjian technology with high altitude of HK $600million
The shares soared by 24.58% on the same day, with a total turnover of HK $1.671 billion, the highest turnover since listing, dozens of times of daily trading.
The stock continued to rise in the next two days, with a three-day surge of nearly 35 per cent, while the stock price hit a record high, while the market value surged nearly HK $5billion. It raises market speculation about whether there is capital to look at the stock.
On November 24, the answer was revealed: according to the Hong Kong stock exchange, Hillard bought 26247.8 million shares of Pioneer Technology (1302. HK) on November 20, with an average price of HK $2.3 per share and a capital of about HK $600 million. After the purchase, hillocks shares accounted for 6.06% of the total equity of pioneer technology.
Delphi capital takes 200 million shares
In addition to the 262 million shares taken by Hillhouse, who has won nearly 200 million shares?
On the evening of November 24, Xianjian technology announced the result: Fude capital.
According to the announcement, Hillard capital and Delphi capital recently transferred all equity of Xianjian technology held by Central Huijin Investment Co., Ltd. (the parent company of China Everbright Holdings Co., Ltd.) (hereinafter referred to as Everbright Holdings) through block trading on the trading day. After the completion of this transaction, Hillard capital and Delphi capital respectively hold 6.06% and 6.00% shares of Xianjian technology.
As an important strategic partner of pioneer technology, we will work together to further accelerate the development of innovative products and deepen the internationalization strategic layout of the company.
As one of the investors of this strategic investment in Xianjian technology, Mr. Li Zhenfu, the founder and CEO of Delphi capital, said: Delphi capital has always attached great importance to Xianjian technology, and we appreciate the determination and investment of pioneer in innovation. In the past five years, Xianjian has invested more than 20% of its sales in R & D every year, which is a rare innovation driven enterprise in China. After the increase, Delphi capital will further deepen the strategic cooperation between the two sides, provide continuous support for the overall value improvement of Xianjian technology, and help Xianjian technology become a leading innovative medical device enterprise.
Who are the people of Xianjian technology?
The company has a comprehensive innovative product layout in the fields of structural heart disease, peripheral vascular disease, heart rhythm management, tumor, cardiopulmonary and neurological fields. It also has the worlds first iron-based absorbable biomaterial platform, and has achieved technological breakthroughs from scratch in many subdivided fields. With its high-quality minimally invasive interventional medical device products, Xianjian technology has brought safe and effective interventional treatment programs to doctors and patients in more than 100 countries and regions around the world.
As of June 30, 2020, the companys revenue was 294 million yuan, a year-on-year decrease of 11.99%; net profit was 84 million yuan, a year-on-year decrease of 5.3%.
Source: Ren Hui, editor in charge of China Fund News_ NBJ9607